All News
Filter News
Found 808,690 articles
-
REVA Medical Announces Closing of Strategic Financing - Aug 09, 2022
8/9/2022
REVA Medical, LLC., a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing.
-
FDA Issues Warning Letters to Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removal
8/9/2022
The U.S. Food and Drug Administration announced it issued three warning letters to companies for introducing mole and skin tag removal products into interstate commerce that are unapproved new drugs, in violation of the Federal Food, Drug, and Cosmetic Act.
-
Arcus Biosciences Announces New Employment Inducement Grants - Aug 09, 2022
8/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 22,100 shares of the Company’s common stock at an exercise price per share of $27.35, which was the closing price on August 8, 2022, and restricted stock units to acquire a total of 11,050 shares of the Company’s common stock.
-
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Intra-Cellular Therapies, Inc. today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
8/9/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Portugal.
-
Appia Bio Appoints Margo Roberts, Ph.D. to its Board of Directors and Names Jason Damiano, Ph.D. as Chief Scientific Officer
8/9/2022
Appia Bio, Inc. today announced the appointment of Margo Roberts, Ph.D. to its board of directors and Jason Damiano, Ph.D. as chief scientific officer (CSO).
-
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Exelixis, Inc. reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
-
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
8/9/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ T cells from induced pluripotent stem cells (iPSCs).
-
Emergent Acquires Evolutionary Biologics, Former L’Oréal President Jim Morrison to Become Full Time CEO of Emergent Effective August 15, 2022
8/9/2022
Emergent Health Corp. announces it has acquired Evolutionary Biologics, Inc.
-
Changing Your Perspective - Mindray Redefines the Possibilities of Point of Care Ultrasound (POCUS)
8/9/2022
Mindray North America, a global leader and developer of healthcare technologies and solutions for ultrasound, patient monitoring, and anesthesia, announced the launch of a new product that is changing the perspective in the Point of Care Ultrasound market: the TE X Ultrasound System.
-
United Spinal Association Appoints Vice President of Tech Access, Director of Chapter Relations, and Director of Employment and DEI Programs
8/9/2022
United Spinal Association announced the appointment of Vice President of Tech Access, Adina Bradshaw, Director of Chapter Relations, Erin Gildner, and Director of Employment and DEI Programs, Lesly St. Louis to its staff.
-
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors
8/9/2022
Cellworks Group, Inc., today announced results from the myCare-203A study, which demonstrate that the Cellworks Biosimulation Platform and Singula™ Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) for non-small cell lung cancer (NSCLC) patients and can provide personalized therapy decision guidance.
-
BioMarker Strategies Announces Publication of Research to Identify Dynamic Biomarkers to Better Predict and Enhance Response to Cetuximab in Patients with Head and Neck/Esophageal Squamous Cell Carcinoma
8/9/2022
BioMarker Strategies announced that the journal CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS has published a manuscript by the Company’s scientists entitled “Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response”.
-
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
8/9/2022
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business updates and reported financial results for the second quarter ended June 30, 2022.
-
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
8/9/2022
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that positive results from a collaborative project with University of Alberta researchers have been accepted for publication in The Journal of Supercritical Fluids.
-
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
8/9/2022
Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the second quarter ended June 30, 2022.
-
Sensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities
8/9/2022
Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrade to its full-featured SRT-100 Vision™ system with new state-of-the-art solid state High-Frequency Ultrasound.
-
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
8/9/2022
KemPharm, Inc. today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications.
-
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
8/9/2022
Summit Therapeutics Inc. announced the successful closing of its fully-subscribed $100 million rights offering.
-
Azenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022
8/9/2022
Azenta, Inc. reported financial results for the third quarter ended June 30, 2022.